Global Treprostinil Sodium Share 2025, Forecast To 2034
26 Mar, 2025
What Is The Current and Historic Market Size Analysis Of The Treprostinil Sodium Market?
The treprostinil sodium market has seen considerable growth due to a variety of factors.
• In the past few years, a significant expansion has been witnessed in the treprostinil sodium market size. The worth is expected to escalate from $1.26 billion in 2024 to reach about $1.39 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.2%.
This considerable growth in the historical timeline is due to rising requisition for treprostinil sodium, amplified prevalence of pulmonary arterial hypertension (PAH); burgeoning demand for treprostinil drugs, escalating consciousness about the crucial role of respiratory health, and the increasing investments funneled into the healthcare infrastructure.
What are the Market Size and Expected Growth Rates for the Treprostinil Sodium Market?
The treprostinil sodium market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, a robust expansion is anticipated in the treprostinil sodium market. It is projected to surge to a size of $1.84 billion by 2029, reflecting a compound annual growth rate (CAGR) of 9.9%.
Factors contributing to this growth during the prediction period include progression in drug delivery technology, a growing preference for combination therapies, increased clinical trials and research funding, an aging population, and escalating healthcare costs. Dominant trends for this time frame involve the evolution of enhanced nebulized and dry powder inhaler formulations, innovations in sustained-release formulations, the use of combination therapies, the invention of more stable and bioavailable oral formulations, and continuing clinical trials investigating new therapeutic uses.
Gain Insights Into The Treprostinil Sodium Global Market Report 2025 With A Free Sample Report Here:
Which Key Drivers Are Propelling The Treprostinil Sodium Market's Growth?
The escalating incidence of lung-related diseases is forecasted to bolster the expansion of the treprostinil sodium market. These diseases, which affect the lungs and the overall respiratory system, interfere with proper breathing and the body's oxygen transportation. The rise in these health conditions is attributed to factors like air pollution, smoking habits, toxins in the environment, and the surge in the elderly population. Treprostinil sodium, a vasodilator, lessens the tension in lung blood vessels, decreases pressure, enhances breathing and presents an adaptable solution for respiratory diseases. For instance, data from the Australian Institute of Health and Welfare in June 2024 reports that in 2022, chronic obstructive pulmonary disease (COPD) led to 7,691 deaths, an equivalent of 29.6 deaths per 100,000 population, contributing to 4.0% of all deaths. Hence, the upsurge in lung diseases is fueling the growth of the treprostinil sodium market.
What Are The Key Segments Within The Global Treprostinil Sodium Market?
The treprostinil sodium market covered in this report is segmented –
1) By Product Type: Injectable, Inhalable, Oral
2) By Applications: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Other Applications
3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Injectable: Subcutaneous Injection, Intravenous Infusion
2) By Inhalable: Inhalation Aerosol, Nebulizer Solution
3) By Oral: Extended-Release Tablets, Oral Suspension
What Emerging Trends Are Influencing The Growth Of The Treprostinil Sodium Market?
Leading enterprises in the treprostinil sodium market are channeling their efforts towards the innovation of superior pulmonary arterial hypertension (PAH) product formulations. The aim of these formulations is to provide improved delivery methods that can maximize therapeutic benefits while limiting side effects. These formulations constitute exact quantities of medications designed to efficiently address PAH. For example, in April 2023, Dr. Reddy's Laboratories, a pharmaceutical firm based in India, unveiled its Treprostinil Injection in the U.S. market, a move that received approval from the Food and Drug Administration, a US-based government entity. This Treprostinil Injection is considered a therapeutic equivalent generic form of Remodulin (treprostinil) Injection that falls under the category of agents known as prostacyclin mimetics. These mimetics are utilized in the treatment of PAH to alleviate symptoms linked with exercising. The product comes in vials containing either 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, or 200 mg/20 mL.
Who Are the Key Players In The Treprostinil Sodium Market?
Major companies operating in the treprostinil sodium market are:
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Dr. Reddy's Laboratories
• United Therapeutics Corporation
• Euroapi SA
• Alembic Pharmaceuticals Ltd.
• Cayman Chemical
• Chirogate International
• Farbe Firma Pvt Ltd.
• Simson Pharma Limited
• YONSUNG Fine Chemicals Co. Ltd.
• Liquidia Corporation
• ChemWerth Inc.
• Mylan Laboratories Limited
• Nuray Chemicals Private Limited
• Endo International plc
• LGM Pharma
• Northern Therapeutics Inc
• KPS Chemicals Pharmaceuticals
What Are The Regional Insights Into The Treprostinil Sodium Market?
North America was the largest region in the treprostinil sodium market in 2024. The regions covered in the treprostinil sodium market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.